BCRX
Price
$11.04
Change
+$0.06 (+0.55%)
Updated
Jun 6 closing price
Capitalization
2.31B
52 days until earnings call
GALT
Price
$1.32
Change
+$0.02 (+1.54%)
Updated
Jun 6 closing price
Capitalization
83.54M
70 days until earnings call
Interact to see
Advertisement

BCRX vs GALT

Header iconBCRX vs GALT Comparison
Open Charts BCRX vs GALTBanner chart's image
BioCryst Pharmaceuticals
Price$11.04
Change+$0.06 (+0.55%)
Volume$4.09M
Capitalization2.31B
Galectin Therapeutics
Price$1.32
Change+$0.02 (+1.54%)
Volume$242.98K
Capitalization83.54M
BCRX vs GALT Comparison Chart
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCRX vs. GALT commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and GALT is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (BCRX: $11.04 vs. GALT: $1.32)
Brand notoriety: BCRX: Notable vs. GALT: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 81% vs. GALT: 138%
Market capitalization -- BCRX: $2.31B vs. GALT: $83.54M
BCRX [@Biotechnology] is valued at $2.31B. GALT’s [@Biotechnology] market capitalization is $83.54M. The market cap for tickers in the [@Biotechnology] industry ranges from $334.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileGALT’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • GALT’s FA Score: 0 green, 5 red.
According to our system of comparison, BCRX is a better buy in the long-term than GALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 3 TA indicator(s) are bullish while GALT’s TA Score has 5 bullish TA indicator(s).

  • BCRX’s TA Score: 3 bullish, 5 bearish.
  • GALT’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, GALT is a better buy in the short-term than BCRX.

Price Growth

BCRX (@Biotechnology) experienced а +2.70% price change this week, while GALT (@Biotechnology) price change was +0.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

BCRX is expected to report earnings on Jul 31, 2025.

GALT is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCRX($2.31B) has a higher market cap than GALT($83.5M). BCRX YTD gains are higher at: 46.809 vs. GALT (2.326). BCRX has higher annual earnings (EBITDA): 47.6M vs. GALT (-40.38M). BCRX has more cash in the bank: 295M vs. GALT (27.1M). GALT has less debt than BCRX: GALT (105M) vs BCRX (795M). BCRX has higher revenues than GALT: BCRX (503M) vs GALT (0).
BCRXGALTBCRX / GALT
Capitalization2.31B83.5M2,766%
EBITDA47.6M-40.38M-118%
Gain YTD46.8092.3262,013%
P/E RatioN/AN/A-
Revenue503M0-
Total Cash295M27.1M1,089%
Total Debt795M105M757%
FUNDAMENTALS RATINGS
BCRX vs GALT: Fundamental Ratings
BCRX
GALT
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
96
Overvalued
PROFIT vs RISK RATING
1..100
69100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3889
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (32) in the Biotechnology industry is somewhat better than the same rating for GALT (96). This means that BCRX’s stock grew somewhat faster than GALT’s over the last 12 months.

BCRX's Profit vs Risk Rating (69) in the Biotechnology industry is in the same range as GALT (100). This means that BCRX’s stock grew similarly to GALT’s over the last 12 months.

BCRX's SMR Rating (100) in the Biotechnology industry is in the same range as GALT (100). This means that BCRX’s stock grew similarly to GALT’s over the last 12 months.

BCRX's Price Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for GALT (89). This means that BCRX’s stock grew somewhat faster than GALT’s over the last 12 months.

BCRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as GALT (100). This means that BCRX’s stock grew similarly to GALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXGALT
RSI
ODDS (%)
Bearish Trend 3 days ago
77%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
80%
Momentum
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
74%
MACD
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 13 days ago
79%
Bullish Trend 3 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 11 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
82%
Aroon
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GDOT9.580.35
+3.79%
Green Dot Corp
SAH73.021.49
+2.08%
Sonic Automotive
MSFT470.382.70
+0.58%
Microsoft Corp
BPMC127.85-0.05
-0.04%
Blueprint Medicines Corp
LEE6.65-0.08
-1.19%
Lee Enterprises

BCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
+0.55%
VCYT - BCRX
46%
Loosely correlated
+1.78%
CRNX - BCRX
40%
Loosely correlated
+2.13%
INSM - BCRX
39%
Loosely correlated
+1.21%
COGT - BCRX
39%
Loosely correlated
+13.52%
VKTX - BCRX
39%
Loosely correlated
+2.92%
More

GALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, GALT has been loosely correlated with BCAB. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if GALT jumps, then BCAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GALT
1D Price
Change %
GALT100%
+1.54%
BCAB - GALT
37%
Loosely correlated
+5.52%
NVO - GALT
32%
Poorly correlated
+2.73%
SNPX - GALT
32%
Poorly correlated
-10.41%
RNAC - GALT
32%
Poorly correlated
+18.15%
ERAS - GALT
27%
Poorly correlated
+1.91%
More